These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 2151405

  • 1. [GnRH-analogs in the therapy of uterine myomatosis].
    Wieacker P, Geisthövel F, Adelberger V, Breckwoldt M.
    Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
    [Abstract] [Full Text] [Related]

  • 2. Gonadotropin-releasing hormone (GnRH) action on uterine leiomyomata is not mediated by uterine GnRH receptors.
    Neuman M, Langer R, Golan A, Bukovsky I, Caspi E, Koch Y.
    Fertil Steril; 1991 Aug; 56(2):364-6. PubMed ID: 1649060
    [No Abstract] [Full Text] [Related]

  • 3. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
    Matta WH, Shaw RW, Nye M.
    Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
    [Abstract] [Full Text] [Related]

  • 4. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A, Vollenhoven B, Sowter M.
    Cochrane Database Syst Rev; 2000 Feb; (2):CD000547. PubMed ID: 10796723
    [Abstract] [Full Text] [Related]

  • 5. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A, Vollenhoven B, Sowter M.
    Cochrane Database Syst Rev; 2001 Feb; (2):CD000547. PubMed ID: 11405968
    [Abstract] [Full Text] [Related]

  • 6. Treatment of uterine fibroids with agonist analogs of gonadotropin-releasing hormone.
    Kessel B, Liu J, Mortola J, Berga S, Yen SS.
    Fertil Steril; 1988 Mar; 49(3):538-41. PubMed ID: 3277869
    [Abstract] [Full Text] [Related]

  • 7. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
    Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, Roark M, Steinkampf MP.
    J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313
    [Abstract] [Full Text] [Related]

  • 8. Pre-surgical treatment of uterine myomas with LH-RH agonists.
    D'Addato F, Repinto A, Andreoli C.
    Clin Exp Obstet Gynecol; 1992 May; 19(1):45-50. PubMed ID: 1535032
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hormonal therapy before surgical treatment for uterine leiomyomas.
    Moghissi KS.
    Surg Gynecol Obstet; 1991 Jun; 172(6):497-502. PubMed ID: 1827931
    [Abstract] [Full Text] [Related]

  • 11. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy.
    Kuhlmann M, Gärtner A, Schindler EM, Regidor PA, Bühler K, Schindler AE.
    Gynecol Endocrinol; 1997 Jun; 11(3):169-74. PubMed ID: 9209897
    [Abstract] [Full Text] [Related]

  • 12. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
    Donnez J, Schrurs B, Gillerot S, Sandow J, Clerckx F.
    Fertil Steril; 1989 Jun; 51(6):947-50. PubMed ID: 2498131
    [Abstract] [Full Text] [Related]

  • 13. Triptorelin to prevent hysterectomy in patients with leiomyomas.
    van Leusden HA.
    Lancet; 1988 Aug 27; 2(8609):508. PubMed ID: 2900426
    [No Abstract] [Full Text] [Related]

  • 14. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
    Friedman AJ, Daly M, Juneau-Norcross M, Rein MS, Fine C, Gleason R, Leboff M.
    J Clin Endocrinol Metab; 1993 Jun 27; 76(6):1439-45. PubMed ID: 8501148
    [Abstract] [Full Text] [Related]

  • 15. Treatment of uterine fibroid with triptorelin before hysterectomy.
    Loong EP, Lo KW.
    Chin Med J (Engl); 1998 Jan 27; 111(1):67-70. PubMed ID: 10322658
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up.
    Letterie GS, Coddington CC, Winkel CA, Shawker TH, Loriaux DL, Collins RL.
    Fertil Steril; 1989 Jun 27; 51(6):951-6. PubMed ID: 2498132
    [Abstract] [Full Text] [Related]

  • 17. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata.
    Wiznitzer A, Marbach M, Hazum E, Insler V, Sharoni Y, Levy J.
    Biochem Biophys Res Commun; 1988 May 16; 152(3):1326-31. PubMed ID: 2837183
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist.
    Friedman AJ, Barbieri RL, Benacerraf BR, Schiff I.
    Fertil Steril; 1987 Oct 16; 48(4):560-4. PubMed ID: 3115833
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of LHRH analogue action in uterine fibroids.
    Shaw RW.
    Horm Res; 1989 Oct 16; 32 Suppl 1():150-3. PubMed ID: 2533145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.